Skip to main content
OpenTrials
Completed

NCT Number: NCT06935123

Impact of Nutritional Supplementation on Sleep Quality

This is a randomized, double-blind, placebo-controlled, 5-arm parallel-group study to evaluate the effects of 4 nutritional supplements on sleep over a 12 week period in healthy U.S. adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Atlantia Clinical Trials Inc., 142 E. Ontario, Suite 1200

Chicago, Illinois, 60611, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be able to give written informed consent.
  • Be between 18-65 years of age (inclusive).
  • Insomnia severity Index score ≤14.
  • PROMIS Sleep Disturbance Questionnaire raw score ≥23
  • Be willing to maintain stable dietary habits and physical activity levels throughout the study period.
  • Willing to consume the study product daily for the duration of the study.

Exclusion criteria

  • Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
  • Participants currently of biological childbearing potential, but not using a continuous effective method of contraception as determined by the investigator.
  • Has a history of drug and/or alcohol abuse.
  • Hypersensitive to the contents of the study product.
  • Participants with work schedules that result in irregular sleep patterns/ or have night-shift employment.
  • High caffeine intake, >400mg/day.
  • Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:
  • Diagnosed Sleep disorders
  • Major psychiatric diagnosis (e.g., bipolar), as diagnosed by a healthcare professional, including major depressive disorder (e.g., clinical depression)
  • Immunocompromised health conditions
  • Currently or recently (in the past 4 weeks) taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:
  • Prescribed sleep medications
  • Prescribed Medications which impact sleep, including but not limited to sedative hypnotics, anxiolytics, and antidepressants.
  • Current or recent (in the past 4 weeks) use of prohibited nutritional and non-nutritional supplements with known or possible sleep effects (e.g. valerian, multivitamins, melatonin)
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
  • Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

Treatment and study plan

Sleep Supplements

Dietary Supplement

Sleep supplements

Placebo

Other

Matching placebo

Primary outcomes

  1. PROMIS Sleep Disturbance 8A

    Time frame: 0, 4, 8, and 12 weeks

    Perceived sleep quality

Secondary outcomes

  1. PROMIS Sleep Related Impairment 8A

    Time frame: 0, 4, 8, and 12 weeks

    Perceived functional impairments during wakefulness associated with sleep problems or impaired alertness.

  2. Insomnia Severity Index (ISI)

    Time frame: 0, 4, 8, and 12 weeks

    Severity of sleep difficulties and satisfaction with sleep

  3. Depression, Anxiety, and Stress Scale - 21 Items (DASS-21)

    Time frame: 0, 4, 8, and 12 weeks

    Severity of general psychological distress and symptoms related to depression, anxiety, and stress

  4. Bristol Stool Scale (BSS)

    Time frame: 0, 4, 8, and 12 weeks

    Stool frequency and consistency

Other outcomes

  1. Safety Objectives

    Time frame: 0, 4, 8, and 12 weeks

    Occurrence of any Adverse Events (AEs/SAEs)

Sponsors and collaborators

Lead sponsor

Pharmavite LLC

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Evaluating Nutritional Supplementation On Sleep Quality

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 20, 2025
Registry last updated
Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.